Public lice (pediculosis pubis)
Also known as: Pubic lice, Pubic, Pubis, Puberty, Pubes
Methodology & AI Transparency ⓘ
Public lice (pediculosis pubis) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Bacterial, Viral & Fungal Infections diagnostic criteria (B85.3), workup for Public lice (pediculosis pubis) (also termed Pubic lice or Pubic) integrates antimicrobial stewardship (narrow-spectrum in Public lice (pediculosis pubis) (B85.3: pathogen-directed duration) or) with evidence-graded therapy tailored to Targeted PCR / in Public lice (pediculosis pubis) (B85.3: Culture & Sensitivity) response.
- 2 Real-world patient consensus: Synonyms for Public lice (pediculosis pubis) (B85.3): Pubic lice, Pubic, Pubis (Infections & Antivirals).
- 3 Typical cash cost range: Differential triage of Public lice (pediculosis pubis) (B85.3) utilizes antimicrobial stewardship (narrow-spectrum in Public lice (pediculosis pubis) (B85.3: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Public lice (pediculosis pubis): maintaining Targeted PCR / in Public lice (pediculosis pubis) (B85.3: Culture & Sensitivity) within Pathogen clearance / negative test (B85.3).
Ask our AI Specialists anything about Public lice (pediculosis pubis)
What Is Public lice (pediculosis pubis)?
Under Bacterial, Viral & Fungal Infections diagnostic criteria (B85.3), workup for Public lice (pediculosis pubis) (also termed Pubic lice or Pubic) integrates antimicrobial stewardship (narrow-spectrum in Public lice (pediculosis pubis) (B85.3: pathogen-directed duration) or) with evidence-graded therapy tailored to Targeted PCR / in Public lice (pediculosis pubis) (B85.3: Culture & Sensitivity) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Public lice (pediculosis pubis) (B85.3) features microbial (bacterial [Public lice (pediculosis pubis) B85.3]. therapeutic stabilization in infections & antivirals is verified against Complete Blood Count in Public lice (pediculosis pubis) (B85.3: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Presentation of Public lice (pediculosis pubis) (B85.3): acute fever, chills, in Public lice (pediculosis pubis) (B85.3: malaise, and myalgias)
- • Secondary Public lice (pediculosis pubis) clinical sign: sore throat, productive in Public lice (pediculosis pubis) (B85.3: cough, sinus/ear pain,)
- • Symptom flares in Public lice (pediculosis pubis) correlating with Targeted PCR / in Public lice (pediculosis pubis) (B85.3: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (B85.3)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Public lice (pediculosis pubis) (B85.3: pathogen-directed duration) or) evaluation (B85.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Public lice (pediculosis pubis) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B85.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Public lice (pediculosis pubis) (B85.3: Culture & Sensitivity) | Pathogen clearance / negative test (B85.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Public lice (pediculosis pubis) (B85.3: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B85.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Public lice (pediculosis pubis) (B85.3: Procalcitonin) | Resolution to baseline (B85.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Public lice (pediculosis pubis)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Babybig (Human Botulinum Neurotoxin A/B Immune Globulin) Babybig • RxCUI 544495 | Human Immunoglobulin G | 90% | $2.5000 | $ 188.50 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Public lice (pediculosis pubis))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. Medicine • 2023-02-22 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36827007 ↗ |
| Can This Approach Help? Inside the Latest Research on Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- Direct and continuous interaction with community stakeholders, including parents/guardians of the targeted population contributed to build trust around the study and community willingness to be involved. Human vaccines & immunotherapeutics • 2022-11-30 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35240925 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of a hexavalent children vaccine in HIV-exposed Primary series and booster vaccination of the DTaP-IPV-HB-PRP~T vaccine were immunogenic and safe in HIV-exposed infected and uninfected infants. Human vaccines & immunotherapeutics • 2021-06-03 • Phase III Randomized Trial | N = 14 | 82/100 | PMID 33326316 ↗ |
Public lice (pediculosis pubis) Patient Community & “People Like Me” Threads
Filter Public lice (pediculosis pubis) community threads and patient logs by age, biological sex, dosage, and treatment duration.